Letter to the Editor

Sir: The recent Glaxo Wellcome–sponsored supplement to the Journal entitled “Beyond SSRIs” provides clinicians with useful information regarding the treatment of depression and discusses our bupropion product. I would like to provide clarification on some aspects of the supplement relating to bupropion.